|
|||||||||
|
|
|
|
|
|
|
|
|
|
|
Prepublished online as a Blood First Edition Paper on January 16, 2003; DOI 10.1182/blood-2002-10-3050.
HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
From the Departments of Internal Medicine,
Biochemistry, Molecular Biophysics, and Genetics, Washington University
School of Medicine, St Louis, MO; and the Department of Pathology and
Laboratory Medicine, University of North Carolina, Chapel Hill.
Hemophilia B is a bleeding disorder resulting from factor IX (FIX)
deficiency that might be treated with gene therapy. Neonatal delivery
would correct the disease sooner than would transfer into adults, and
could reduce immunological responses. Neonatal mice were injected
intravenously with a Moloney murine leukemia virus-based
retroviral vector (RV) expressing canine FIX (cFIX). They achieved
150% to 280% of normal cFIX antigen levels in plasma (100% is 5 µg/mL), which was functional in vitro and in vivo. Three newborn
hemophilia B dogs that were injected intravenously with RV achieved
12% to 36% of normal cFIX antigen levels, which improved coagulation
tests. Only one mild bleed has occurred during 14 total months of
evaluation. This is the first demonstration of prolonged expression
after neonatal gene therapy for hemophilia B in mice or dogs. Most
animals failed to make antibodies to cFIX, demonstrating that neonatal
gene transfer may induce tolerance. Although hepatocytes from newborns
replicate, those from adults do not. Adult mice therefore received
hepatocyte growth factor to induce hepatocyte replication prior to
intravenous injection of RV. This resulted in expression of 35% of
normal cFIX antigen levels for 11 months, although all mice produced
anti-cFIX antibodies. This is the first demonstration that high levels
of FIX activity can be achieved with an RV in adults without a partial
hepatectomy to induce hepatocyte replication. We conclude that
RV-mediated hepatic gene therapy is effective for treating hemophilia B
in mice and dogs, although the immune system may complicate gene transfer in adults.
(Blood. 2003;101:3924-3932) Hemophilia B is a sex-linked disorder due to
deficiency of factor IX (FIX) activity that affects 1 in
30 000 males.1 Hepatic gene therapy could result in the
continuous secretion of FIX into the blood and improve bleeding
symptoms. Achieving more than 10% of normal activity should prevent
most spontaneous bleeds, whereas 1% of normal activity should reduce,
but not prevent, bleeding. There has been recent success in using
hepatic gene therapy to express therapeutic levels of FIX in
mice.2 For example, lentiviral vectors resulted in FIX
antigen levels that were 2% to 7% of normal3,4; adeno-associated virus (AAV) vectors resulted in levels that
were 10% to 40% of normal5-9 or 400% of
normal10; adenoviral vectors resulted in levels
that were 8% of normal11 or 60% to 4100% of
normal12-16; and plasmids resulted in levels that were 7%
to 80% of normal.17-19 In addition, intramuscular
injection of AAV vectors resulted in 3% to 7% of
normal5,20,21 or 1000% of normal levels,22
whereas other nonhepatic approaches generally result in lower long-term
expression.2
Gene therapy appears to be less efficacious in large-animal models than
in mice. In some cases, lower expression was obtained despite
the use of a dose of vector per body weight similar to that
used in mice, although in other cases lower expression could be
attributed at least in part to the use of a lower relative dose of
vector. For example, delivery of AAV vectors to the liver of hemophilia
B dogs resulted in expression of 1%,7 1% to
4%,23 or 5% to 12%24 of normal canine FIX
(cFIX) antigen levels, whereas intramuscular injection of an AAV vector
resulted in expression of 0.5% to 2% of normal
levels.25-27 Antigen levels were 0.1% of normal after
delivery of a Moloney murine leukemia virus (MLV)-based retroviral
vector (RV) after partial hepatectomy28 or 1% of normal
after electroporation of muscle.29 Although expression from an adenoviral vector was high in hemophilia B dogs at 270% of
normal, it was transient owing to immune responses.12 In primates, 3 of 5 animals expressed human FIX (hFIX) antigen levels that
were 3% to 8% of normal after portal vein or hepatic artery injection
of an AAV vector, although 2 animals had undetectable expression.30 Expression was 80% of normal after
intravenous injection of an adenoviral vector into primates, but was
transient and associated with the development of inhibitory
antibodies.31
Results from these animal studies have led to 2 phase 1 clinical trials
of gene therapy for hemophilia B in humans. Intramuscular injection of
an AAV vector expressing hFIX may have caused a slight (less than 1%)
increase in hFIX functional activity and a modest (less than 50%)
decrease in factor usage, but these may represent assay variation and a
placebo effect, respectively.32 Data are not yet available
from the second trial, which involves hepatic artery injection of an
AAV vector.33 Thus, it is unclear if AAV vectors will
achieve a full therapeutic effect in patients, and it remains possible
that other approaches might be as, or more, efficient.
Recent advances in MLV-based RV technology have led us to re-evaluate
its efficacy for gene therapy for hemophilia B. Although MLV-based RVs transduce only dividing cells,34 it was
recently shown that they transduce hepatocytes from newborn
mice35,36 and dogs37 without a stimulus for
replication, or hepatocytes from adults after the administration of
hepatocyte growth factor (HGF) to induce replication.38-42
In addition, use of the human Reagents
Retroviral vector construction and production
Animal procedures National Institutes of Health (NIH) and US Department of Agriculature (USDA) guidelines for the care and use of animals in research were followed. Neonatal mice were obtained after breeding BALB/c mice (Jackson Laboratory, Bar Harbor, ME), heterozygous mucopolysaccharidosis VII (MPS VII) mice from a C57BL/6 (B6.C-H-2bm1) background,51 or hemophilia B mice from a mixed 129 × C57BL/6 background,52 and RVs (1 × 1010 TU/kg) were injected intravenously at 2 to 3 days after birth via the temporal vein. Six-week-old mice were used for adult transduction. For BALB/c mice, approximately 400 µL PBS solution containing 0.29 mg/mL HGF and 0.46 mg/mL dextran sulfate with average molecular weight 5000 kD was injected intraperitoneally at 5.8 mg/kg HGF every 3 hours from 0 to 12 hours. Control BALB/c mice received PBS at the same times. Mice received approximately 400 µL of 3.3 × 109 TU/kg per dose hAAT-cFIX-WPRE intravenously via the tail vein at 30, 36, and 48 hours after the first dose of HGF or PBS. For adult hemophilia B mice, only RV was injected. For analysis of antigen levels, blood was drawn from the retro-orbital plexus with a capillary tube, and diluted with porcine heparin (Elkins-Sinn, Cherry Hill, NJ) to 250 U/mL. For analysis of coagulation activity, blood was mixed with a 1/10 vol 3.2% sodium citrate.Hemophilia B puppies from the Chapel Hill colony53 were produced by mating hemophilia B dogs, and their phenotype was confirmed by a prolonged whole blood clotting time.12 At 2 days after birth, 4 doses, at 5 mL RV each, were injected intravenously over 5 minutes at 4-hour intervals via an external jugular catheter. G08 and G42 were male and weighed 0.378 and 0.561 kg, respectively. G18 was female and weighed 0.35 kg. Immunoassay for cFIX For mouse samples, the first antibody was the rabbit anti-cFIX antibody used for immunostaining, diluted 1:200 in 0.1 M NaHCO3, pH 9.5. For dog samples, the first antibody was a 1:500 dilution of a mouse monoclonal anti-hFIX antibody (Roche, Indianapolis, IN). Wells were blocked with Tris (tris(hydroxymethyl)aminomethane)-buffered saline (TBS) (40 mM Tris-HCl, 150 mM NaCl, pH 7.4) with 5% nonfat dry milk (Schnucks Grocery, St Louis, MO) (TBS-milk) and washed 6 times with TBS with 0.05% Tween 20 (TBS-Tween) between each step. Samples were diluted in TBS-milk and incubated for 2 hours at 37°C. For the mouse and canine assays, a 1:500 or 1:200 dilution, respectively, of an HRP-conjugated sheep anti-cFIX IgG (SACIX-HRP; Affinity Biologicals, Ancaster, ON, Canada) was incubated for 2 hours at 37°C, and the assay was developed with 3, 3', 5', 5'-tetramethylbenzidine. The cFIX was undetectable in plasma from mice or hemophilia B dogs. Standards were dilutions of pooled plasma from normal Chapel Hill dogs, which was assumed to have 5 µg/mL cFIX.Anti-cFIX IgG antibody assay Enzyme-linked immunosorbent assay (ELISA) plates were coated with 5 µg/mL purified cFIX in PBS, then blocked with TBS-milk. Control wells for nonspecific binding were coated with PBS. Plasma was diluted 1:100 or higher in TBS-milk, and incubated overnight at 4°C. For samples from mice, an HRP-coupled antimouse IgG (Roche) was diluted 1:200 and incubated with the samples at 37°C for 2 hours, followed by development for 3 minutes with tetramethylbenzidine. For dog samples, an HRP-coupled sheep anticanine IgG antibody (Serotec, Raleigh, NC) was used as the second antibody. If the optical density (OD) exceeded 0.5 for samples that were captured with cFIX, the sample was diluted further. The background increased with age for samples from BALB/c mice, but remained low for other samples. The signal was determined by subtracting the OD of the PBS-coated well from the OD obtained with the cFIX-coated well, and multiplying by the dilution factor used for the plasma sample.Coagulation assays The activated partial thromboplastin time (aPTT) assay incubated 100 µL aPTT reagent (Organon Teknika, Durham, NC) with 100 µL plasma at 37°C for 5 minutes; then 100 µL of 25 mM CaCl2 was added and the time to clot formation measured with a Fibrosystem BBL fibrometer (Becton Dickinson, Cockeysville, MD). For samples from RV-treated normal mice, assays used 75 µL hFIX-deficient human, 5 µL RV-treated mouse, and 20 µL cFIX-deficient dog plasma. The times were compared with a standard curve obtained with the use of 75 µL hFIX-deficient human, 5 µL normal mouse, 0 to 20 µL normal dog, and 20 to 0 µL cFIX-deficient dog plasma. If necessary, samples from RV-treated mice were diluted with normal mouse plasma. For samples from RV-treated hemophilia B mice, assays used 75 µL hFIX-deficient human, 10 µL RV-treated hemophilia B mouse, and 15 µL cFIX-deficient dog plasma; and the standards used 75 µL hFIX-deficient human, 10 µL hemophilia B mouse, 0 to 15 µL normal dog, and 15 to 0 µL cFIX-deficient dog plasma. The aPTT from RV-treated dogs used 100 µL plasma, and standards were created by mixing plasma from normal and hemophilia B dogs from the Chapel Hill colony. The tail-clip bleeding assay was performed on 4-month-old mice after cutting the tail where the diameter was 2 mm as previously described10 except the end point was bleeding from the tail at 15 minutes after clip was performed.DNA analysis for RV DNA sequences DNA was isolated from organs and 100 ng was analyzed by real-time polymerase chain reaction (PCR) with the use of Taqman technology (Applied Biosystems, Rockville, MD) as described previously.36 DNA from nontransduced mice was isolated and amplified at the same time as DNA from the experimental mice to demonstrate a lack of contamination. Standards contained 0.5 copies or fewer of a WPRE-containing RV per diploid genome.36 The sensitivity of the assay was 0.002 copies per cell.
Generation of an RV expressing cFIX The cFIX cDNA was cloned into an MLV-based RV vector downstream of the hAAT promoter and upstream of the WPRE (Figure 1A). This vector does not contain a selectable marker to avoid the expression of unnecessary sequences that might provoke an immune response. This was used to generate an amphotropic RV.
cFIX expression and antibody response in BALB/c mice We first tested whether hAAT-cFIX-WPRE could result in therapeutic levels of cFIX in plasma after transfer into neonatal or adult BALB/c mice. Because neonatal mice have sufficient hepatocyte replication to achieve gene transfer with an MLV-based vector without a stimulus for replication, a single dose of 1 × 107 TU (1 × 1010 TU/kg) was injected intravenously at 2 to 3 days after birth without preceding it with HGF. For transfer into adult mice, HGF was given prior to the injection of RV to stimulate the hepatocyte replication that is needed for transduction, as diagrammed in Figure 1B. Control adult mice received PBS prior to the RV to assess the level of expression that could be achieved without induction of hepatocyte replication. Beginning at 30 hours after the first dose of HGF (or PBS), 3 equal doses of RV were injected intravenously for these adult animals, for a cumulative dose that was identical to the dose used in neonatal mice per body weight (1 × 1010 TU/kg). Preliminary experiments demonstrated that hepatocyte replication occurred at these times after the initiation of HGF administration in mice (C.G., K.P.P., data not shown).BALB/c mice that were transduced as newborns achieved 14.3 ± 4.1
µg/mL cFIX (2.9-fold normal) in blood at 1 month after transduction, which was maintained at stable levels at 3 months (Figure
2A). The BALB/c mice that were transduced
as adults after HGF administration achieved 2.8 ± 0.6 µg/mL cFIX
in plasma at 1 month, which was maintained at 1.75 ± 0.3 µg/mL
(35% of normal) at 11 months (Figure 2B). The cFIX level in the adults
that received PBS prior to RV administration was only 0.033 ± 0.015
µg/mL at 1 month after transduction, and declined thereafter (Figure
2C). We conclude that intravenous injection of RV into newborns results
in 8-fold higher antigen levels than in adults that were treated with
HGF prior to intravenous injection of RV, but that both approaches
achieved therapeutic levels. Prior administration of HGF to adults
increased cFIX levels by 86-fold over levels in adult animals
that received the same dose of RV without preceding HGF
(P = .0002).
Although anti-FIX antibodies can develop after repeated injections of FIX protein or with many gene therapy approaches, 0 of 7 BALB/c mice that were transduced as newborns developed detectable anti-cFIX IgG antibodies (Figure 2D). In contrast, 3 of 3 BALB/c mice that were treated as adults with RV after HGF administration (Figure 2E) and 6 of 6 BALB/c mice that received gene transfer as adults without preceding HGF administration (Figure 2F) developed antibodies within 1 week after transduction. Although these antibodies did not appear to affect antigen levels for most mice, the 2 animals with the highest levels of antibody had a rapid drop in their antigen levels (Figure 2C,F filled-in symbols). Fisher exact test demonstrated that detectable antibody formation was statistically less common in BALB/c mice that were transduced as newborns than in mice that were transduced as adults after HGF administration (P = .008) or in mice that were transduced as adults without HGF (P = .0006). cFIX expression and antibody response in hemophilia B mice The effect of gene transfer upon bleeding manifestations was assessed in hemophilia B mice that were present on a mixed 129 × C57BL/6 background. These mice were generated by homologous recombination into the region that contains the promoter through exon 3, and do not express detectable murine FIX. Neonatal transduction resulted in 8.1 ± 1.9 µg/mL cFIX in plasma (Figure 3A; 162% of normal), which was stable for 11 months after transduction. Levels of cFIX antigen were undetectable at all times after injection into adult hemophilia B mice that did not receive preceding HGF (Figure 3B). An attempt to transduce adult hemophilia B mice after HGF administration was unsuccessful owing to the peritoneal bleeding induced by multiple intraperitoneal injections (not shown).
Hemophilia B mice were tested to determine if they developed antibodies to cFIX. Fifteen of 17 mice that were transduced as newborns had no detectable antibody at any time of evaluation, whereas 2 of these mice had a low level of antibody that resolved spontaneously and never affected the antigen levels or the coagulation activity (Figure 3C and data not shown). In contrast, 6 of 6 hemophilia B mice that received RV as adults without preceding HGF developed antibodies (Figure 3D). Development of antibodies at any time of evaluation was statistically less likely in mice that were treated as newborns than in adult mice that received RV without preceding HGF (P = .0003 with Fisher exact test). Functional activity of cFIX in mice We also tested if the cFIX present in RV-treated mice was functional. Two aPTT assays specific for cFIX functional activity were developed for analysis of plasma from normal or hemophilia B mice as detailed in "Materials and methods" and shown in Figure 4A. The cFIX functional activity correlated well with the antigen levels for normal BALB/c mice that were transduced as adults after HGF administration, and for most hemophilia B mice that were treated with RV as neonates (Figure 4B). However, a few animals with antigen levels that exceeded 300% of normal had approximately 50% of the expected functional activity. All hemophilia B mice that were treated with RV as newborns rapidly achieved hemostasis after tail clip, although untreated hemophilia B mice did not (Figure 4C). We conclude that the cFIX produced after neonatal or adult gene therapy was functional, although some animals with very high antigen levels had somewhat lower activity than expected.
Organ distribution of vector To evaluate the RV distribution, real-time PCR was performed on DNA isolated from liver and other organs with the use of the WPRE sequences to detect the RV, and mouse -actin sequences to normalize for the amount of DNA. DNA was analyzed from 3 C57BL/6 normal
mice that were transduced as neonates and that, at the time of being
killed at 10 months, had levels of expression (5.9 ± 2.5
µg/mL) similar to those observed in the BALB/c and
hemophilia B mice. After neonatal transduction, the liver contained an
average of 1.09 ± 0.06 (SEM) copies of the RV per cell (Figure
5A). The spleen and the kidney had
0.11 ± 0.010 and 0.06 ± 0.004 copies of RV per cell, which are
10% and 6%, respectively, of the values in liver. In mice that were
treated as adults with HGF followed by RV, there were 0.67 ± 0.1
copies of the RV per cell in the liver at 11 months after transduction
(Figure 5B). RV sequences were undetectable (fewer than 0.002 copies
per cell) in kidney, heart, brain, large intestine, and small
intestine. DNA was detectable in other organs, but the copy number was
lower than 7% of that in liver. We conclude that the liver was the
major target organ after transduction of adult or neonatal mice with an
MLV-based RV. The higher cFIX expression in neonatal-transduced than in adult-transduced mice appeared to be due to a higher transduction efficiency.
Neonatal gene therapy in hemophilia B dogs RV transduction was performed on neonatal hemophilia B dogs from the Chapel Hill colony, which have a missense mutation that changes amino acid 379 from glycine to glutamate, and results in less than 1% of normal antigenic and functional activity in plasma.53 G08 and G18 received 1.3 × 1010 TU/kg, whereas G42 received 0.8 × 1010 TU/kg of hAAT-cFIX-WPRE at 2 to 3 days after birth as detailed in "Materials and methods." The average platelet count fell from 250 ± 156 × 109/L prior to injection to 131 ± 24 × 109/L at 24 hours (P = .03 for 24 hours versus pre-gene transfer values) and 123 ±15.1 × 109/L at 48 hours (P = .01 for 48 hours versus pre-gene transfer values), but returned to normal by day 4 (Figure 6A). The average white blood cell (WBC) count increased from 11.2 ± 2 × 109/L (11 200 ± 2000/µL) prior to gene therapy to 17.7 ± 5 × 109/L (17 700 ± 5000/µL) at 24 hours and 22.5 ± 2.6 × 109/L (22 500 ± 2600/µL) at 48 hours (Figure 6B), but these elevations were not statistically significant (P = .4 and P = .06 when the 24 hours and 48 hours were compared with the pre-gene therapy values, respectively), and the upper limit of normal for WBC count in dogs is higher than in humans. For G08, the WBC count has been normal for most samples at 4 days or later. For G18, the WBC count increased dramatically at 2 weeks after gene transfer when he became clinically ill and was humanely killed; at necropsy, G18 was found to have pyelonephritis that we believe is unrelated to the gene transfer. For G42, the WBC count has remained slightly elevated at most times for unclear reasons. The hematocrit was low for all dogs at early times (Figure 6C); this may be due to their age. CPK values were occasionally modestly elevated (Figure 6D). The alkaline phosphatase, GT, and BUN were elevated
for 1 to 2 weeks after gene transfer (Figure 6E-G); these
probably represent physiologically normal elevations in newborns, as
the elevated levels were present prior to gene therapy, and
analysis in 6 untreated normal neonatal dogs showed similar levels
(data not shown). The creatinine was normal or below normal at most times (Figures 6H). The serum glutamic-oxaloacetic transaminase (SGOT), serum glutamic-pyruvic transaminase (SGPT),
bilirubin, and amylase levels were within normal limits, and the
albumin and total protein levels were either normal or below normal at all times for all dogs (data not shown).
RV-treated dogs were evaluated for cFIX functional activity and
antigen levels and for correction of the bleeding phenotype. The whole
blood clotting time was corrected to the normal range at 1 week or
later after gene transfer for all dogs (Figure
7A), and the aPTT was shortened but not
normalized (Figure 7B). The relative amount of functional activity was
determined by comparing the results of the aPTT with a standard curve
created by mixing plasma from normal and hemophilia B dogs. The
functional cFIX activity averaged 3.1% ± 0.3% for G08,
6.7% ± 2.5% for G18, and 2.5% ± 0.3% for G42 (Figure 7C).
Antigen levels that were determined by immunoassay were 9.9% of normal
(0.5 µg/mL) for G08 for 11 months, 36% of normal (1.8 µg/mL) for
G18 at 1 week, and 9.7% of normal (0.5 µg/mL) for G42 at 10 weeks
(Figure 7D). Although cFIX levels were higher at 2 weeks for G18, this
may reflect an acute-phase response from the pyelonephritis inducing
the hAAT promoter in the RV. The percentage of cFIX that was functional was determined by dividing the percentage of normal cFIX activity by
the percentage of normal antigen levels for the same sample, and was
32.4% ± 2.8% for G08, 9.7% ± 1.8% for G18, and
25.5% ± 2.1% for G42. Thus, the cFIX was not fully functional even
with below-normal antigen levels. One mild episode of bleeding between the shoulder blades in G08 at 4 months after transduction resolved with
2 doses of plasma containing 5 U/kg cFIX at 24-hour intervals, whereas the other dogs have never bled. No anti-cFIX antibodies were
detected in any dogs at any time (Figure 7E).
Neonatal RV gene therapy corrects the bleeding phenotype in mice and dogs Neonatal injection of an RV expressing cFIX resulted in plasma cFIX antigen levels that were 2.8-fold (BALB/c), 1.6-fold (hemophilia B 129 × C57BL/6), and 1.5-fold (C57BL/6 mice; data not shown) the level found in normal dogs. These levels compare favorably with those achieved with most other gene therapy approaches in mice (reviewed in "Introduction"), although they are lower than in some studies after intramuscular injection of an AAV1 vector22 or intravenous injection of an adenoviral vector.14-16 The average cFIX antigen level in the 3 hemophilia B dogs was considerably lower at 18.5% of normal, although this still exceeds that observed in most other gene therapy studies in hemophilia B dogs (reviewed in "Introduction"), and is similar to that achieved with liver-directed gene therapy with an AAV vector with a similar promoter.24 It is unclear why expression after neonatal transduction was only 9% as high in dogs when compared with mice that received a similar dose of RV per kilogram of body weight. Similarly, expression was lower in neonatal MPS VII dogs37 than in mice.36 The higher cFIX expression here than in a previous study that used an MLV-based RV in dogs28 is probably due at least in part to higher expression per copy owing to a stronger promoter and inclusion of the WPRE. Neonatal transduction is relatively specific for the liver, which contained in excess of 10-fold more copies of DNA than did the kidney and spleen in this study as well as in a previous study in which more organs were analyzed.36 Although DNA distribution was not analyzed in dogs in this study, the copy number at 5 days after gene transfer was high in liver and spleen and was much lower in other organs in a previous study.37There was a modest (less than 50%) decline in the percentage of cFIX
that was functional for some mice with above-normal antigen levels,
although the protein was fully functional when antigen levels were
normal or lower. However, the RV-treated hemophilia B dogs had only
22.5% of the expected functional cFIX activity on the basis of their
antigen levels even with below-normal antigen levels. A similar
reduction in the percentage of cFIX that was functional was observed in
mice when above-normal levels of FIX were achieved after intravenous
injection of an adenoviral15 or intramuscular injection of
an AAV122 vector in mice. This may represent reduced
efficiency in an overexpressing cell of posttranslational
modifications, such as This is the first report of using neonatal gene therapy to achieve long-term correction of hemophilia B in either mice or dogs. Adenoviral14 and AAV8 vectors resulted in only transient expression after neonatal delivery, which may be due to the instability of nonintegrated vectors in rapidly dividing cells, or to other causes such as promoter attenuation. The ability of an RV to integrate into the host cell chromosome and the longevity of hepatocytes54 are probably responsible for the durability of this neonatal approach. Similarly, neonatal gene therapy with an RV achieved long-term expression of factor VIII in hemophilia A mice.35 Neonatal gene transfer has the potential to reduce immune responses, as newborn immune systems are immature.55 Indeed, in this study, antibody responses were much less likely after neonatal gene transfer to BALB/c or hemophilia B 129 × C57BL/6 mice than they were after transfer into adult mice of the same strains. Similarly, no antibodies were detected in the neonatal transduced dogs, although a caveat here is that the Chapel Hill colony of hemophilia B dogs rarely produced antibodies after injection of cFIX protein or gene therapy with cFIX-expressing vectors. Although the neonatal RV gene therapy approach is promising, there are 5 concerns about using this approach in humans. First, the dogs had a modest decrease in their platelet counts at 24 and 48 hours after gene transfer. A similar decrease in the number of platelets from 238 ×109/L to 86 ×109/L occurred at 24 hours after neonatal intravenous injection of an RV into 5 MPS VII dogs, although there were no other complete blood count (CBC) abnormalities (L.X., Mark Haskins, and K.P.P., unpublished data, 2002). Because schistocytes were rare or undetectable on the peripheral blood smear and the total bilirubin level was below 5.13 µM (0.3 mg/dL) for 8 dogs that were evaluated at 24 hours after gene transfer, the decrease in platelets was probably not due to severe disseminated intravascular coagulation, although an insufficient amount of blood was available to perform coagulation studies or test for fibrin degradation products. In contrast to results in dogs, platelets did not fall at 24 or 48 hours after intravenous injection of 1 × 1010 TU/kg hAAT-cFIX-WPRE at 3 days after birth in mice (data not shown). In addition, for normal dogs that received a lower dose (2.5 × 109 TU/kg) of an RV expressing human factor IX as newborns, the drop in platelets was more modest (183 ±26 × 109/L at 24 hours and 175 ±104 × 109/L at 48 hours), which suggests that the drop is dose related. Further studies will attempt to determine why platelets fall in dogs and if the RV induces inflammatory responses. A second concern of neonatal gene transfer is that insertional mutagenesis could result in the development of liver cancer. Although we believe that this risk is low, mice and dogs will be followed for the long term for this possible complication prior to applying this approach for hemophilia B. Third, the risk of antibody formation needs to be better defined in large animals, including primates. Fourth, sperm will be analyzed once males undergo puberty to determine if germ line transmission occurs, although newborn males should not have replicating germ cells, and RV DNA was not detected in testis after neonatal gene transfer in mice36 or dogs37 in previous studies. Finally, the exact percentage of hepatocytes that are replicating in newborn humans is unclear, although their rapid growth makes it likely that it should be sufficient to achieve gene transfer. HGF-potentiated RV transfer into adult mice achieves therapeutic levels of expression This study demonstrated that 35% of normal cFIX levels were achieved for 11 months with transfer of an MLV-based RV into adults after replication was induced with HGF. This is the first demonstration that injection of purified HGF protein prior to an RV can result in long-term expression of a therapeutic gene, although others have previously demonstrated that HGF potentiates RV transduction,38-41 and we showed that intramuscular injection of an adenoviral vector expressing HGF increased RV transduction and improved clinical efficacy in MPS VII mice.42 The level of cFIX achieved at late times after transfer into adult BALB/c mice (1.75 µg/mL) was only 19% of the average value observed in 3 different stains after transfer into neonatal mice (9.3 µg/mL) despite use of the same dose of RV per kg body weight. Similarly, the DNA copy number was lower after adult than neonatal transduction. The higher transduction in neonates may reflect higher levels of hepatocyte replication in newborns than in HGF-treated adults, or may be due to other factors.HGF-potentiated RV transfer into adults achieved therapeutic levels of expression that compare favorably with the results obtained with other vectors in adult mice (reviewed in "Introduction"). Although lentiviral vectors are believed by some,3 but not all,4 to efficiently transduce nonreplicating hepatocytes, the level of FIX achieved here is greater than 10-fold higher than that achieved with a lentiviral vector without a partial hepatectomy. It is unclear, however, if this is due to more efficient transfer of the MLV-based RV into the liver or to greater expression per copy. In addition, this system for delivering an MLV-based RV was relatively specific for the liver. In contrast, intravenous injection of a lentiviral vector resulted in a high RV DNA copy number in spleen and bone marrow in addition to liver,56 although other organs had very few copies, and the earlier time of analysis in the lentiviral vector study may have affected the result. MLV-based RV-mediated gene therapy might be easier to implement for adults than newborns, as adults are more qualified to grant informed consent, and an MLV-based RV has already been injected into adult patients with hemophilia A without adverse effects.57 However, most of the concerns noted above for neonatal gene transfer need to be addressed prior to implementing this approach in human adults. In addition, it would be necessary to demonstrate that transient administration of HGF is safe, although it has been efficacious and well tolerated in animal models of liver disease58 and no overt adverse effects were noted in this or previous38-42 studies. Finally, immune modulation may be necessary at the time of gene therapy, given that antibody responses occurred in all animals that were transduced as adults.
We thank Kathy High, Roland Herzog, and Valder Arruda for the cFIX cDNA; for providing purified cFIX and assistance with immunoassays; and for shipping mice to us. We thank Hui-Feng Lin and Darrel Stafford for allowing us to use the hemophilia B mice and Marie Roberts for breeding mice.
Submitted October 7, 2002; accepted December 24, 2002.
Prepublished online as Blood First Edition Paper, January 16, 2003; DOI 10.1182/blood- 2002-10-3050.
Supported by National Institutes of Health grants DK48028 (K.P.P.), R24 HL63098 (T.C.N.), and DK57586 (M.S.S.), and a Judith Graham Pool fellowship from the National Hemophilia Foundation (L.X.).
The publication costs of this article were defrayed in part by page charge payment. Therefore, and solely to indicate this fact, this article is hereby marked "advertisement" in accordance with 18 U.S.C. section 1734.
Reprints: Katherine P. Ponder, Department of Internal Medicine, Washington University School of Medicine, 660 S Euclid Ave, St Louis, MO 63110; e-mail: kponder{at}im.wustl.edu.
1. Lozier JN, Kessler CM. Clinical aspects and therapy of hemophilia. In: Hoffman R,Benz EJ,Shattil SJ, et al., eds. Hematology: Basic Principles and Practice. New York, NY: Churchill Livingstone; 2000:1883-1904. 2. VandenDriessche T, Collen D, Chuah MK. Viral vector-mediated gene therapy for hemophilia. Curr Gene Ther. 2001;1:301-315[CrossRef][Medline] [Order article via Infotrieve]. 3. Follenzi A, Sabatino G, Lombardo A, Boccaccio C, Naldini L. Efficient gene delivery and targeted expression to hepatocytes in vivo by improved lentiviral vectors. Hum Gene Ther. 2002;13:243-260[CrossRef][Medline] [Order article via Infotrieve].
4.
Park F, Ohashi K, Kay MA.
Therapeutic levels of human factor VIII and IX using HIV-1-based lentiviral vectors in mouse liver.
Blood.
2000;96:1173-1176
5.
Nathwani AC, Davidoff A, Hanawa H, Zhou JF, Vanin EF, Nienhuis AW.
Factors influencing in vivo transduction by recombinant adeno-associated viral vectors expressing the human factor IX cDNA.
Blood.
2001;97:1258-1265
6.
Mingozzi F, Schuttrumpf J, Arruda VR, et al.
Improved hepatic gene transfer by using an adeno-associated virus serotype 5 vector.
J Virol.
2002;76:10497-10502 7. Snyder RO, Miao C, Meuse L, et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med. 1999;5:64-70[CrossRef][Medline] [Order article via Infotrieve].
8.
Nakai H, Herzog RW, Hagstrom JN, et al.
Adeno-associated viral vector-mediated gene transfer of human blood coagulation factor IX into mouse liver.
Blood.
1998;91:4600-4607 9. Snyder RO, Miao CH, Patijn GA, et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet. 1997;16:270-276[CrossRef][Medline] [Order article via Infotrieve].
10.
Wang L, Takabe K, Bidlingmaier SM, Ill CR, Verma IM.
Sustained correction of bleeding disorder in hemophilia B mice by gene therapy.
Proc Natl Acad Sci U S A.
1999;96:3906-3910 11. Smith TA, Mehaffey MG, Kayda DB, et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nat Genet. 1993;5:397-402[CrossRef][Medline] [Order article via Infotrieve].
12.
Kay MA, Landen CN, Rothenberg SR, et al.
In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in hemophilia B dogs.
Proc Natl Acad Sci U S A.
1994;91:2353-2357
13.
Dai Y, Schwarz EM, Gu D, Zhang WW, Sarvetnick N, Verma IM.
Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression.
Proc Natl Acad Sci U S A.
1995;92:1401-1405
14.
Walter J, You Q, Hagstrom JN, Sands M, High KA.
Successful expression of human factor IX following repeat administration of adenoviral vector in mice.
Proc Natl Acad Sci U S A.
1996;93:3056-3061
15.
Kung SH, Hagstrom JN, Cass D, et al.
Human factor IX corrects the bleeding diathesis of mice with hemophilia B.
Blood.
1998;91:784-790
16.
Ehrhardt A, Kay MA.
A new adenoviral helper-dependent vector results in long-term therapeutic levels of human coagulation factor IX at low doses in vivo.
Blood.
2002;99:3923-3930 17. Yant SR, Meuse L, Chiu W, Ivics Z, Izsvak Z, Kay MA. Somatic integration and long-term transgene expression in normal and haemophilic mice using a DNA transposon system. Nat Genet. 2000;25:35-41[CrossRef][Medline] [Order article via Infotrieve]. 18. Miao CH, Thompson AR, Loeb K, Ye X. Long-term and therapeutic-level hepatic gene expression of human factor IX after naked plasmid transfer in vivo. Mol Ther. 2001;3:947-957[CrossRef][Medline] [Order article via Infotrieve]. 19. Olivares EC, Hollis RP, Chalberg TW, Meuse L, Kay MA, Calos MP. Site-specific genomic integration produces therapeutic factor IX levels in mice. Nat Biotechnol. 2002;20:1124-1128[CrossRef][Medline] [Order article via Infotrieve].
20.
Hagstrom JN, Couto LB, Scallan C, et al.
Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter.
Blood.
2000;95:2536-2542
21.
Herzog RW, Hagstrom JN, Kung SH, et al.
Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus.
Proc Natl Acad Sci U S A.
1997;94:5804-5809 22. Chao H, Liu Y, Rabinowitz J, Li C, Samulski RJ, Walsh CE. Several log increase in therapeutic transgene delivery by distinct adeno-associated viral serotype vectors. Mol Ther. 2000;2:619-623[CrossRef][Medline] [Order article via Infotrieve]. 23. Wang L, Nichols TC, Read MS, Bellinger DA, Verma IM. Sustained expression of therapeutic level of factor IX in hemophilia B dogs by AAV-mediated gene therapy in liver. Mol Ther. 2000;1:154-158[CrossRef][Medline] [Order article via Infotrieve].
24.
Mount JD, Herzog RW, Tillson DM, et al.
Sustained phenotypic correction of hemophilia B dogs with a factor IX null mutation by liver-directed gene therapy.
Blood.
2002;99:2670-2676 25. Herzog RW, Yang EY, Couto LB, et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nat Med. 1999;5:56-63[CrossRef][Medline] [Order article via Infotrieve]. 26. Herzog RW, Mount JD, Arruda VR, High KA, Lothrop CD Jr. Muscle-directed gene transfer and transient immune suppression result in sustained partial correction of canine hemophilia B caused by a null mutation. Mol Ther. 2001;4:192-200[CrossRef][Medline] [Order article via Infotrieve]. 27. Chao H, Samulski R, Bellinger D, Monahan P, Nichols T, Walsh C. Persistent expression of canine factor IX in hemophilia B canines. Gene Ther. 1999;6:1695-1704[CrossRef][Medline] [Order article via Infotrieve].
28.
Kay MA, Rothenberg S, Landen CN, et al.
In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs.
Science.
1993;262:117-119 29. Fewell JG, MacLaughlin F, Mehta V, et al. Gene therapy for the treatment of hemophilia B using PINC-formulated plasmid delivered to muscle with electroporation. Mol Ther. 2001;3:574-583[CrossRef][Medline] [Order article via Infotrieve].
30.
Nathwani AC, Davidoff AM, Hanawa H, et al.
Sustained high-level expression of human factor IX (hFIX) after liver-targeted delivery of recombinant adeno-associated virus encoding the hFIX gene in rhesus macaques.
Blood.
2002;100:1662-1669
31.
Lozier JN, Metzger ME, Donahue RE, Morgan RA.
Adenovirus-mediated expression of human coagulation factor IX in the rhesus macaque is associated with dose-limiting toxicity.
Blood.
1999;94:3968-3975 32. Kay MA, Manno CS, Ragni MV, et al. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector. Nat Genet. 2000;24:257-261[CrossRef][Medline] [Order article via Infotrieve]. 33. Mickelson CA. Regulatory issues of the RAC. Hum Gene Ther. 2000;11:2176-2178.
34.
Miller DG, Adam MA, Miller AD.
Gene transfer by retroviral vectors occurs only in cells that are actively replicating at the time of infection.
Mol Cell Biol.
1990;10:4239-4242
35.
VandenDriessche T, Vanslembrouck V, Goovaerts I, et al.
Long-term expression of human coagulation factor VIII and correction of hemophilia A after in vivo retroviral gene transfer in factor VIII-deficient mice.
Proc Natl Acad Sci U S A.
1999;96:10379-10384 36. Xu L, Mango RL, Sands MS, Haskins ME, Ellinwood NM, Ponder KP. Evaluation of pathological manifestations of disease in mucopolysaccharidosis VII mice after neonatal hepatic gene therapy. Mol Ther. 2002;6:745-758[CrossRef][Medline] [Order article via Infotrieve]. 37. Xu L, Haskins ME, Gao C, et al. Transduction of hepatocytes after neonatal delivery of a Moloney murine leukemia virus-based retroviral vector results in long-term expression of beta-glucuronidase in mucopolysaccharidosis VII dogs. Mol Ther. 2002;5:141-153[CrossRef][Medline] [Order article via Infotrieve]. 38. Patijn GA, Lieber A, Schowalter DB, Schwall R, Kay MA. Hepatocyte growth factor induces hepatocyte proliferation in vivo and allows for efficient retroviral-mediated gene transfer in mice. Hepatology. 1998;28:707-716[CrossRef]. 39. Kosai KI, Finegold MJ, Thi-Huynh BT, et al. Retrovirus-mediated in vivo gene transfer in the replicating liver using recombinant hepatocyte growth factor without liver injury of partial hepatectomy. Hum Gene Ther. 1998;9:1293-1301[Medline] [Order article via Infotrieve]. 40. Bosch A, McCray PB Jr, Walters KS, et al. Effects of keratinocyte and hepatocyte growth factor in vivo: implications for retrovirus-mediated gene transfer to liver. Hum Gene Ther. 1998;9:1747-1754[Medline] [Order article via Infotrieve]. 41. Forbes SJ, Themis M, Alison MR, et al. Tri-iodothyronine and a deleted form of hepatocyte growth factor act synergistically to enhance liver proliferation and enable in vivo retroviral gene transfer via the peripheral venous system. Gene Ther. 2000;7:784-789[CrossRef][Medline] [Order article via Infotrieve]. 42. Gao C, Sands MS, Haskins ME, Ponder KP. Delivery of a retroviral vector expressing human beta-glucuronidase to the liver and spleen decreases lysosomal storage in mucopolysaccharidosis VII mice. Mol Ther. 2000;2:233-244[CrossRef][Medline] [Order article via Infotrieve]. 43. Okuyama T, Huber RM, Bowling W, et al. Liver-directed gene therapy: a retroviral vector with a complete LTR and the ApoE enhancer-alpha 1-antitrypsin promoter dramatically increases expression of human alpha 1-antitrypsin in vivo. Hum Gene Ther. 1996;7:637-645[Medline] [Order article via Infotrieve].
44.
Le M, Okuyama T, Cai SR, et al.
Therapeutic levels of functional human factor X in rats after retroviral-mediated hepatic gene therapy.
Blood.
1997;89:1254-1259
45.
Zufferey R, Donello JE, Trono D, Hope TJ.
Woodchuck hepatitis virus posttranscriptional regulatory element enhances expression of transgenes delivered by retroviral vectors.
J Virol.
1999;73:2886-2892 46. Gao C, Jokerst R, Gondipalli P, et al. Lipopolysaccharide potentiates the effect of hepatocyte growth factor upon hepatocyte replication in rats by augmenting AP-1 DNA binding activity. Hepatology. 1999;30:1405-1416[CrossRef][Medline] [Order article via Infotrieve].
47.
Evans JP, Watzke HH, Ware JL, Stafford DW, High KA.
Molecular cloning of a cDNA encoding canine factor IX.
Blood.
1989;74:207-212
48.
Markowitz D, Goff S, Bank A.
A safe packaging line for gene transfer: separating viral genes on two different plasmids.
J Virol.
1988;62:1120-1124 49. Markowitz D, Goff S, Bank A. Construction and use of a safe and efficient amphotropic packaging cell line. Virology. 1988;167:400-409[Medline] [Order article via Infotrieve].
50.
Ory DS, Neugeboren BA, Mulligan RC.
A stable human-derived packaging cell line for production of high titer retrovirus/vesicular stomatitis virus G pseudotypes.
Proc Natl Acad Sci U S A.
1996;93:11400-11406 51. Birkenmeier EH, Davisson MT, Beamer WG, et al. Murine mucopolysaccharidosis type VII: characterization of a mouse with beta-glucuronidase deficiency. J Clin Invest. 1989;83:1258-1266[Medline] [Order article via Infotrieve].
52.
Lin HF, Maeda N, Smithies O, Straight DL, Stafford DW.
A coagulation factor IX-deficient mouse model for human hemophilia B.
Blood.
1997;90:3962-3966
53.
Evans JP, Brinkhous KM, Brayer GD, Reisner HM, High KA.
Canine hemophilia B resulting from a point mutation with unusual consequences.
Proc Natl Acad Sci U S A.
1989;86:10095-10099 54. Ponder KP. Analysis of liver development, regeneration, and carcinogenesis by genetic marking studies. FASEB J. 1996;10:673-682[Abstract]. 55. Sarzotti M. Immunologic tolerance. Curr Opin Hematol. 1997;4:48-52[Medline] [Order article via Infotrieve]. 56. Pan D, Gunther R, Duan W, et al. Biodistribution and toxicity studies of VSVG-pseudotyped lentiviral vector after intravenous administration in mice with the observation of in vivo transduction of bone marrow. Mol Ther. 2002;6:19-29[CrossRef][Medline] [Order article via Infotrieve]. 57. Recombinant DNA advisory committee. Human gene transfer protocol #9902-284: phase I multicenter, single-treatment, dose escalation study of human factor VIII vector for treatment of severe hemophilia A. Hum Gene Ther. 2000;11:1503-1506. 58. Oe S, Hiros T, Fujii H, et al. Continuous intravenous infusion of deleted form of hepatocyte growth factor attenuates hepatic ischemia-reperfusion injury in rats. J Hepatol. 2001;34:832-839[CrossRef][Medline] [Order article via Infotrieve].
© 2003 by The American Society of Hematology.
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
|
 |
|
  G. P. Niemeyer, R. W. Herzog, J. Mount, V. R. Arruda, D. M. Tillson, J. Hathcock, F. W. van Ginkel, K. A. High, and C. D. Lothrop Jr Long-term correction of inhibitor-prone hemophilia B dogs treated with liver-directed AAV2-mediated factor IX gene therapy Blood, January 22, 2009; 113(4): 797 - 806. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. A. High Update on Progress and Hurdles in Novel Genetic Therapies for Hemophilia Hematology, January 1, 2007; 2007(1): 466 - 472. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. Dobrzynski and R. W. Herzog Tolerance Induction by Viral In Vivo Gene Transfer Clin. Med. Res., November 1, 2005; 3(4): 234 - 240. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kang, L. Xie, D. T. Tran, C. S. Stein, M. Hickey, B. L. Davidson, and P. B. McCray Jr Persistent expression of factor VIII in vivo following nonprimate lentiviral gene transfer Blood, September 1, 2005; 106(5): 1552 - 1558. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. Xu, T. C. Nichols, R. Sarkar, S. McCorquodale, D. A. Bellinger, and K. P. Ponder Absence of a desmopressin response after therapeutic expression of factor VIII in hemophilia A dogs with liver-directed neonatal gene therapy PNAS, April 26, 2005; 102(17): 6080 - 6085. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Schuettrumpf, R. W. Herzog, A. Schlachterman, A. Kaufhold, D. W. Stafford, and V. R. Arruda Factor IX variants improve gene therapy efficacy for hemophilia B Blood, March 15, 2005; 105(6): 2316 - 2323. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. N. Waddington, M. S. Nivsarkar, A. R. Mistry, S. M. K. Buckley, G. Kemball-Cook, K. L. Mosley, K. Mitrophanous, P. Radcliffe, M. V. Holder, M. Brittan, et al. Permanent phenotypic correction of hemophilia B in immunocompetent mice by prenatal gene therapy Blood, November 1, 2004; 104(9): 2714 - 2721. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. E. Sabatino, E. Armstrong, S. Edmonson, Y.-L. Liu, M. Pleimes, J. Schuettrumpf, J. Fitzgerald, R. W. Herzog, V. R. Arruda, and K. A. High Novel hemophilia B mouse models exhibiting a range of mutations in the Factor IX gene Blood, November 1, 2004; 104(9): 2767 - 2774. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Dobrzynski, F. Mingozzi, Y.-L. Liu, E. Bendo, O. Cao, L. Wang, and R. W. Herzog Induction of antigen-specific CD4+ T-cell anergy and deletion by in vivo viral gene transfer Blood, August 15, 2004; 104(4): 969 - 977. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Zhang, L. Xu, M. E. Haskins, and K. Parker Ponder Neonatal gene transfer with a retroviral vector results in tolerance to human factor IX in mice and dogs Blood, January 1, 2004; 103(1): 143 - 151. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. VandenDriessche Challenges and progress in gene therapy for hemophilia A Blood, September 15, 2003; 102(6): 1938 - 1939. [Full Text] [PDF]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
 |
 |
 |
|||||||
 |
 |
 |
 |
 |
 |
 |
 |
||
| Copyright © 2003 by American Society of Hematology Online ISSN: 1528-0020 | |||||||||
Top
Abstract
Introduction
1-antitrypsin (hAAT)
promoter
70°C in phosphate-buffered saline (PBS) (137 mM NaCl, 2.7 mM KCl, 10.1 mM
Na2HPO4, and 1.8 mM KH2PO4, pH
7.4).
+), the 403-nt
human 
)
or hemophilia B mice (HB; 
). (B) In vitro coagulation activity for
plasma from RV-treated mice. Normal BALB/c mice whose expression levels
are shown in Figure 
